Filtered By:
Condition: Heart Disease
Cancer: Cancer
Management: Profits and Losses
This page shows you your search results in order of date.
Order by Relevance | Date
Total 21 results found since Jan 2013.
ERLEADA ® (apalutamide), First-and-Only Next-Generation Androgen Receptor Inhibitor with Once-Daily, Single-Tablet Option, Now Available in the U.S.
HORSHAM, Pa., April 3, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the availability of an additional tablet strength of ERLEADA® (apalutamide) in the United States. The introduction of the 240mg tablet provides the first-and-only option for a once-daily, single-tablet Androgen Receptor Inhibitor (ARI) approved for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC) and for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).With two strengths available, healthcare professionals will have the flexibility to...
Source: Johnson and Johnson - April 3, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Janssen Data at ASCO GU Support Ambition to Transform Treatment of Prostate and Bladder Cancer Through Precision Medicine and Early Intervention
RARITAN, N.J., February 13, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced plans to present more than 20 abstracts featuring seven oncology therapies from its robust portfolio and pipeline at the annual American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, taking place in San Francisco on February 16-18. Building on more than a decade of leadership in the development of medicines for people diagnosed with GU cancers, Janssen will present data demonstrating its ambition to advance patient-centered treatment through precision medicine, real-world evidence a...
Source: Johnson and Johnson - February 13, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Real-World Study Confirms Benefit of XARELTO ® (rivaroxaban) for Secondary Prevention of Venous Thromboembolism in Cancer Patients
TITUSVILLE, NJ, December 9, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced observational data from eight years of clinical practice showing that the oral Factor Xa inhibitor XARELTO® (rivaroxaban) is associated with comparable effectiveness and safety to the Factor Xa inhibitor apixaban for the treatment of cancer-associated thromboembolism (CAT) in a broad cohort of patients with various cancer types. Patients with CAT are at a higher risk of venous thromboembolism (VTE), which is the second-leading cause of death in people with cancer.1Data from the Observational Study in Cancer-A...
Source: Johnson and Johnson - December 9, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
New ERLEADA ® (apalutamide) Analysis Demonstrates Rapid, Deep Prostate-Specific Antigen (PSA) Response in Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
SAN FRANCISCO, Feb. 14, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new real-world evidence data showing the initiation of ERLEADA® (apalutamide) results in high rates of rapid and deep prostate-specific antigen (PSA) response among patients with metastatic castration-sensitive prostate cancer (mCSPC). In a separate post-hoc analysis of the registrational Phase 3 SPARTAN and TITAN studies, rapid and deep PSA responses with ERLEADA® were associated with improvement in patient-reported outcomes (PROs) related to quality of life, physical wellbeing, pain, and fatigue intensity. The...
Source: Johnson and Johnson - February 14, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen Data at ASCO GU Demonstrate Longstanding Leadership in Prostate Cancer and Commitment to Advancing Potential New Therapeutic Options for Genitourinary Cancers
Raritan, NJ, Feb. 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that 17 presentations will be featured at the 2022 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, taking place in San Francisco and virtually from February 17-19. Building on its long-term leadership in prostate cancer, Janssen is committed to advancing innovative treatments and transforming patient experiences, while focusing on research that may drive better outcomes for people across the genitourinary cancer spectrum. Data to be presented include Phase 3 results for the selective ...
Source: Johnson and Johnson - February 1, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
FDA Approves Two New Indications for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, Dec. 20, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved two pediatric indications for XARELTO® (rivaroxaban): the treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients from birth to less than 18 years after at least five days of initial parenteral (injected or intravenous) anticoagulant treatment; and thromboprophylaxis (prevention of blood clots and blood-clot related events) in children aged two years and older with congenital heart disease who have...
Source: Johnson and Johnson - December 21, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
ERLEADA ® (apalutamide) Oral Presentations Demonstrate Importance of Prostate Specific Antigen (PSA) as Key Efficacy Indicator and Show Strong Patient Adherence Rates
September 11, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data demonstrating robust prostate-specific antigen (PSA) response and strong adherence rates in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) treated with ERLEADA® (apalutamide) in the real-world clinical setting. The strong PSA response was also seen in a separate post-hoc analysis that showed a correlation between rapid and deep PSA response and prolonged survival in both metastatic castration-sensitive prostate cancer (mCSPC) and nmCRPC. The post-hoc analysis also suppor...
Source: Johnson and Johnson - September 12, 2021 Category: Pharmaceuticals Source Type: news
Janssen Demonstrates Commitment to Advancing Science and Innovation in the Treatment of Solid Tumors at ESMO Annual Congress
September 8, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than ten data presentations from its lung cancer, bladder cancer and prostate cancer portfolio and pipeline will be featured during the European Society for Medical Oncology (ESMO) Annual Congress 2021 virtual meeting, September 16–21. Further details about these data and the science Janssen is advancing will be made available throughout ESMO via the Janssen Oncology Virtual Newsroom.“With a diverse oncology portfolio and pipeline spanning bladder cancer, lung cancer and prostate cancer, Janssen...
Source: Johnson and Johnson - September 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Striving to Deliver Better Outcomes: Janssen to Showcase Commitment to Advancing Science for Genitourinary Cancers at AUA 2021
August 31, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today multiple company-sponsored presentations in prostate and bladder cancers will be highlighted at the virtual 2021 American Urological Association Annual Meeting (AUA 2021), September 10-13. “Janssen maintains a strong commitment to advancing innovation and new therapeutic options for patients with genitourinary malignancies. As the treatment of genitourinary cancers becomes more complex, we continue to work with urologists and their teams to improve outcomes for patients across the continuum of disease,” sai...
Source: Johnson and Johnson - August 31, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
National Burden Estimates of healthy life lost in India, 2017: an analysis using direct mortality data and indirect disability data
Publication date: December 2019Source: The Lancet Global Health, Volume 7, Issue 12Author(s): Geetha R Menon, Lucky Singh, Palak Sharma, Priyanka Yadav, Shweta Sharma, Shrikant Kalaskar, Harpreet Singh, Srividya Adinarayanan, Vasna Joshua, Vaitheeswaran Kulothungan, Jeetendra Yadav, Leah K Watson, Shaza A Fadel, Wilson Suraweera, M Vishnu Vardhana Rao, R S Dhaliwal, Rehana Begum, Prabha Sati, Dean T Jamison, Prabhat JhaSummaryBackgroundMany countries, including India, seek locally constructed disease burden estimates comprising mortality and loss of health to aid priority setting for the prevention and treatment of disease...
Source: The Lancet Global Health - November 9, 2019 Category: International Medicine & Public Health Source Type: research
‘Salty’ Concern: Tackling High Salt Consumption in China
Veena S. Kulkarni, Associate Professor, Department of Criminology, Sociology and Geography, Arkansas State University, USA; and Raghav Gaiha, (Hon.) Professorial Research Fellow, Global Development Institute, University of Manchester, England.By Veena S. Kulkarni and Raghav GaihaNEW DELHI, India and JONESBORO, US, Oct 7 2019 (IPS) China’s almost meteoric transition from a being a low income to a middle income country within a span of four decades is often perceived as a miracle analogous to the post Second World War Japanese economic development experience. China’s GDP rose from $200 current United States dollars (US$ ...
Source: IPS Inter Press Service - Health - October 7, 2019 Category: International Medicine & Public Health Authors: Veena Kulkarni and Raghav Gaiha Tags: Asia-Pacific Development & Aid Economy & Trade Food & Agriculture Food Sustainability Globalisation Headlines Health Labour TerraViva United Nations Barilla Center for Food and Nutrition Foundation (BCFN) Source Type: news
Regular activity may help some people stay 'fat and fit'
Conclusion
As people often say, if exercise was a medicine, it would be hailed as a miracle cure. This study suggests that what we already know about the benefits of exercise may extend to reducing risk of cardiovascular disease for middle aged and older people, even if they are overweight or obese.
But the study has some limitations. This type of study can't prove that one factor – exercise – is responsible for the lower risk of heart attack and stroke among overweight or obese people who exercise more. It's possible that other factors are important – for example people's income may be linked to their opportuniti...
Source: NHS News Feed - March 2, 2017 Category: Consumer Health News Tags: Obesity Lifestyle/exercise Heart/lungs Source Type: news
Our Sedentary Lifestyles Cost About 5 Million Lives A Year
By Kate Kelland
LONDON (Reuters) - A study of one million people has found that physical inactivity costs the global economy $67.5 billion a year in healthcare and productivity losses, but an hour a day of exercise could eliminate most of that.
Sedentary lifestyles are linked to increased risks of heart disease, diabetes and cancer, researchers found, but activity - such as brisk walking - could counter the higher likelihood of early death linked with sitting for eight or more hours a day.
Such inactivity is estimated to cause more than 5 million deaths a year - almost as many as smoking, which the World Health Organi...
Source: Healthy Living - The Huffington Post - July 28, 2016 Category: Consumer Health News Source Type: news
Needs of Internally Displaced Women and Children in Baghdad, Karbala, and Kirkuk, Iraq
Conclusions
The vulnerability of this population is great, and the emotional trauma of multiple displacements, kidnapping and deaths from intentional violence is great. While some aid is reaching families, much more is needed. Though Iraq is a middle income country, reaching the IDPs in central Iraq will take much more in international assistance than is currently being received. Unfortunately, at this time of great need, assistance is being cut back throughout the region because of lack of funding.10 The local civil society organizations which have sprung up in many locations to assist IDPs, offer an avenue for targeting ...
Source: PLOS Currents Disasters - June 10, 2016 Category: Global & Universal Authors: Gilbert Burnham Source Type: research
